Johnson & Johnson (J&J) has announced that the clinical trials of its new vaccine for the Ebola virus will commence in 2015.
J&Js ultimate goal is develop a vaccine that can protect against both the Zaire and Sudan strains of Ebola. GlaxoSmithKline also announced plans this month to test one of their Ebola vaccines before the end of the year.
The initial phase I trials begin with healthy volunteers with a goal of determining if the vaccines are safe and if they will provoke a protective immune response. J&J has not said where the trials will be conducted or how many subjects will be involved.
The clinical trials, which include technology from Bavarian Nordic, is being fast-tracked amid one of the worlds worst outbreaks of Ebola. Most recently, the latest scare occurred in Florida when it was announced that a man was being tested for the virus at a Miami hospital. Results came back negative. The latest numbers from the United Nations indicate that approximately 1,900 people in West Africa have died from Ebola since March.
According to Johnson & Johnson, its vaccine provided complete protecting against the Zaire strain of Ebola when tested on macaque monkeys. Immunization consists of two injections, one to prime the immune system and a second to boost the response. How safe the Ebola vaccinations will be has yet to be seen and only time will tell.
Johnson & Johnson has a long history in creating quality medical products, however, it is also no stranger to dangerous drugs. Over the years, several batches of Tylenol have been recalled due to an increased risk of liver damage. Other J&J drugs such as Xarelto and Risperdal have also been under attack due to health risks associated with these drugs.
Have you or someone you love suffered health problems that you believe may be linked to a dangerous drug? The class action attorneys at Gordon & Doner can help you determine what your legal rights are and if you may be eligible to file a claim.
Follow Gordon & Doneron